Company intelligence / Profile preview

Archeus Technologies

Madison, Wisconsin, United States

Ownership: Private
Development stage: Other

Overview

Archeus Technologies received FDA IND clearance for ART-101 (PSMA-targeting small molecule) for mCRPC, showing higher tumor uptake/retention and lower normal tissue toxicity compared to current PSMA agents; multiple Phase 1 trials to initiate in 2025 for ART-101 and ARC-706. Preclinical data for NM600 and ARC-706 suggest enhanced immune response and curative potential when combined with immunotherapy.

Therapeutic areas: Oncology
Modalities: Small moleculeRadiopharmaceutical
Industry: Biotech

Drug pipeline

4 assets

90Y-NM600

3 more assets in the full pipeline.

Request access →

Partnerships

Wisconsin Alumni Research Foundation (WARF)University of Wisconsin–Madison (UW–Madison)Isthmus Project (investment and commercialization support)

Beyond the preview

Go deeper on Archeus Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Archeus Technologies.

Explore the full profile